2025
SJR Q1
JCR Q1 · 8,6
5 matched articles
SCIE
Journal detail
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
- Publisher
- John Wiley & Sons Inc.
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1939004119395116
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,565
- Quartile Q1
- H-Index 114
- Cites/doc 9,61
- Docs (3y) 250
- Cites (3y) 2.593
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 8,6
- 5Y JIF 9
- JCI 0,71
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Bioengineering Q1
- Biomedical Engineering Q1
- Medicine (miscellaneous) Q1
- Nanoscience and Nanotechnology Q1
Areas
- Chemical Engineering
- Engineering
- Materials Science
- Medicine
WoS categories
- Nanoscience & Nanotechnology | Medicine, Research & Experimental
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,565 | 8,6 | 9 | 0,71 | Q2 | 114 |
| 2024 | Q1 | Q1 | 1,666 | 8,2 | 8,8 | 0,7 | Q2 | 104 |
| 2023 | Q1 | Q1 | 1,571 | 6,9 | 8,2 | 0,68 | Q2 | 104 |
| 2022 | Q1 | Q1 | 1,588 | 8,6 | 9,1 | 0,74 | Q2 | 104 |
| 2021 | Q1 | Q1 | 1,621 | 9,4 | 9,6 | 0,75 | Q2 | 104 |
| 2020 | Q1 | Q1 | 2,175 | 9,2 | 9 | 0,97 | Q2 | 104 |
| 2019 | Q1 | Q1 | 2,16 | 7,7 | 7 | 0,95 | Q2 | 104 |
| 2018 | — | Q1 | — | 6,1 | 5,9 | 0,95 | Q2 | — |
| 2017 | Q1 | Q1 | 1,987 | 6,3 | 5,5 | 0,9 | Q2 | 104 |
| 2016 | Q1 | Q1 | 1,708 | 4,8 | 4,6 | — | — | 104 |
| 2015 | Q1 | Q1 | 1,41 | 4,1 | 4,5 | — | — | 104 |
| 2014 | Q1 | Q1 | 1,619 | 4,5 | 5,2 | — | — | 104 |
| 2013 | Q1 | Q1 | 1,821 | 4,2 | 5,4 | — | — | 104 |
| 2012 | Q1 | Q1 | 2,317 | 5,7 | 6,3 | — | — | 104 |
| 2011 | Q1 | Q1 | 2,273 | 5,2 | 5,2 | — | — | 104 |
| 2010 | Q1 | Q2 | 0,945 | 2,2 | 2,2 | — | — | 104 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 21/191 |
| 2025 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 33/148 |
| 2024 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 22/195 |
| 2024 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 31/147 |
| 2023 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 22/189 |
| 2023 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 33/141 |
| 2022 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 19/136 |
| 2022 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | Q2 | 29/108 |
| 2021 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 20/139 |
| 2021 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | Q2 | 30/109 |
| 2020 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 12/140 |
| 2020 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 22/106 |
| 2019 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 12/139 |
| 2019 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 20/103 |
| 2018 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 13/136 |
| 2018 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | Q2 | 26/94 |
| 2017 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | Q2 | 12/133 |
| 2017 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | Q2 | 21/92 |
| 2016 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 17/128 |
| 2016 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | — | 23/87 |
| 2015 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 25/124 |
| 2015 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | — | 28/83 |
| 2014 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 21/123 |
| 2014 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | — | 22/80 |
| 2013 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 20/124 |
| 2013 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | — | 20/73 |
| 2012 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 13/121 |
| 2012 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | — | 14/69 |
| 2011 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | — | 12/112 |
| 2011 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q1 | — | 15/66 |
| 2010 | MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q2 | — | 49/106 |
| 2010 | NANOSCIENCE & NANOTECHNOLOGY | SCIE | Q2 | — | 30/64 |